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Abstract RNA interference is the process that double-stranded
RNA induces the homology-dependent degradation of cognate
mRNA mediated by 21^23 nucleotide short interfering RNA
(siRNA). Here, we describe a simple virus vector for e⁄cient
delivery of siRNA into mammalian cells utilizing the well-de-
¢ned H1-RNA promoter and conventional adenovirus. In this
pilot study, p53 was targeted by this vector. Our results dem-
onstrate e⁄cient and speci¢c knock-down of p53 in breast can-
cer MCF-7 and lung carcinoma A549 cells and indicate a pro-
spective application of this siRNA expressing recombinant
adenovirus system in functional genomics, cancer gene therapy
and virus inhibition.
1 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
Key words: RNA interference; Short interfering RNA; p53;
Adenovirus; Functional genomics
1. Introduction
RNA interference (RNAi) is an ancient evolutionarily con-
served process [1]. Ever since synthetic 21^23 nucleotide short
interfering RNA (siRNA) was shown to induce e⁄cient RNAi
in mammalian cells [2,3], siRNA has been routinely used in
gene silencing by transfection of chemically synthesized si-
RNA [4]. To circumvent the high cost of synthetic siRNA and
in order to establish stable gene knock-down cell lines by
siRNA, several plasmid vector systems were designed to pro-
duce siRNA inside cells driven by RNA polymerase III-de-
pendent promoters such as U6 and H1-RNA gene promoters
[5^9]. With these plasmid vectors, the phenotypes of gene
silencing could be observed by stable transfection of cells
[5]. Nevertheless, transient siRNA expression, low and vari-
able transfection e⁄ciency remains the problems for chemi-
cally synthesized and vector derived siRNA. Recently, several
virus vectors have been developed for e⁄cient delivery of
siRNA into mammalian cells [10^12]. Retroviral vectors
were designed to produce siRNA driven by either U6 or
H1-RNA promoter for e⁄cient, uniform delivery and imme-
diate selection of stable knock-down cells [10,11]. Meanwhile,
an adenovirus vector using RNA polymerase II CMV pro-
moter was also developed and demonstrated to mediate gene
silencing both in vitro and in vivo [12]. With the completion
of whole-genome sequencing of several organisms and exten-
sive studies of functional genomics and proteomics, more and
more genes will be validated for gene therapy. To expand the
strategy of RNAi to human cancer gene therapy, we devel-
oped a simple adenovirus system utilizing the well de¢ned
polymerase III H1-RNA promoter to drive e⁄cient expres-
sion of siRNA in mammalian cells. Our results demonstrate
e⁄cient and speci¢c knock-down of p53 in di¡erent cell lines
and indicate a promising application of this adenovirus system
in functional genomics, cancer gene therapy and virus inhibi-
tion.
2. Materials and methods
2.1. Plasmid constructs
The RNA polymerase III H1-RNA gene promoter was used in our
study. H1-RNA promoter was cloned into the promoterless shuttle
vector pShuttle (Stratagene, La Jolla, CA, USA) to get a new shuttle
vector designated pShuttle-H1 (Fig. 1) which can drive the expression
of siRNA in recombinant adenovirus. For convenient cloning and
con¢rmation, the BglII site of the original promoterless pShuttle vec-
tor was converted to EcoRI site by site-directed mutagenesis (Strata-
gene) with the following primers: forward 5P-GCTTGTCGACT-
CGAAGACCTGGGCGTGGTTAAGGG-3P, reverse 5P-CCCTTA-
ACCACGCCCAGGTCTTCGAGTCGACAAGC-3P. H1-RNA pro-
moter was cut from pSUPER (kindly provided by Reuven Agami,
The Netherlands Cancer Institute, Amsterdam, The Netherlands)
with XbaI and HindIII, cloned into the same restriction sites of the
promoterless mutagenized pShuttle (BglII to EcoRI) and con¢rmed by
dideoxy sequencing (GATC Biotech AG, Konstanz, Germany). The
64 nt oligonucleotides encoding human p53 speci¢c siRNA were
5P-GATCCCCGACTCCAGTGGTAATCTACTTCAAGAGAGTA-
GATTACCACTGGAGTCTTTTTGGAAA-3P and 5P-AGCTTTTC-
CAAAAAGACTCCAGTGGTAATCTACTCTCTTGAAGTAGAT-
TACCACTGGAGTCGGG-3P as described [5]. These oligonucleo-
tides were annealed and ligated to the BglII and HindIII sites of
pShuttle-H1 to get plasmid pShuttle-H1-p53 and con¢rmed by EcoRI
digestion. A pSUPER-p53 was also constructed as described by
Brummelkamp [5]. The inserted sequences were con¢rmed by dideoxy
sequencing.
2.2. Production of recombinant adenovirus
Here, we employed the e⁄cient homologous recombination machin-
ery in Escherichia coli [13]. A recombinant adenovirus was produced
by a double-recombination event between cotransformed adenoviral
backbone plasmid pAdEasy-1 (Stratagene) and a linearized shuttle
vector. pShuttle-H1 and pShuttle-H1-p53 were linearized with PmeI
and cotransformed with pAdEasy-1 into BJ5183 cells by electropora-
tion or linearized shuttle vectors were transformed into BJ5183-AD-1
cells (Stratagene) by a standard CaCl2 method. Positive clones were
selected and con¢rmed by DNA miniprep and PacI digestion. Plas-
mids from correct clones were ampli¢ed by transforming into DH5K
cells followed by DNA maxiprep (Qiagen, Hilden, Germany). The
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resulting adenoviral DNA (AdH1-p53 or AdH1-empty) was linearized
with PacI and puri¢ed by ethanol precipitation (Fig. 2A). The pack-
aging cell line AD-293 was grown in DMEM with 10% FBS supple-
mented with 100 U/ml penicillin and 100 Wg/ml streptomycin. 1.5U106
cells were plated in a 25 cm2 £ask the day before transfection. Cells
were transfected by 24 Wg of Dosper liposome (Roche, Basel, Switzer-
land) with 6 Wg of PacI linearized adenoviral DNA (Fig. 2A). The
next day, the medium containing the transfection mix was replaced
with 6 ml of growth medium. Transfected cells were incubated for
additional 7^10 days and medium was changed every 2^3 days. Virus
was harvested, ampli¢ed and titered according to the manufacturer’s
instructions (Stratagene).
2.3. Cell transfection
Breast cancer MCF-7 and lung carcinoma A549 cells were grown in
DMEM with 10% FBS supplemented with 100 U/ml penicillin and
100 Wg/ml streptomycin. The day before virus infection, 0.3U106
MCF-7 or A549 cells were plated in each well of 6-well plates. The
following day, cells were incubated with recombinant virus (AdH1-
p53 or AdH1-empty) at MOI of 10^20 at 37‡C. After adsorption for
1^2 h, 2 ml of fresh growth medium was added and cells were placed
in the incubator for additional 2^3 days.
2.4. Western blot
Cells were harvested at the indicated time points after virus infec-
tion, washed once with cold PBS and lysed in lysis bu¡er (150 mM
NaCl, 50 mM Tris^HCl, pH7.4, 2 mM EDTA, 1% NP-40) containing
protease inhibitors (Boehringer Mannheim, Germany). Total proteins
(30 Wg per lane) were resolved on a 8% SDS^polyacrylamide gel and
transferred onto a nylon membrane and incubated with anti-p53
(Pharmingen, San Diego, CA, USA) and anti-actin (Sigma) monoclo-
nal antibodies, followed by incubation with horseradish-peroxidase
conjugated anti-mouse IgG secondary antibody (Sigma). The bands
were visualized by using the enhanced chemiluminescence system
(Pierce, Rockford, IL, USA).
3. Results and discussion
Successful application of RNAi in functional genomics and
proteomics, cancer gene therapy and virus protection depends
on the e⁄cient delivery of siRNA into mammalian cells. In
this study, we utilized a commercially available adenovirus
system and the well-de¢ned polymerase III H1-RNA pro-
moter to deliver siRNA expressing cassette into cells and to
silence a speci¢c gene in human cancer cells.
RNAi or RNA silencing is the process that double-stranded
RNA induces the homology-dependent degradation of cog-
nate mRNA [1]. This is an ancient and ubiquitous antiviral
system used by organisms to maintain the integrity of the
genome, to defend cells against viral infection and to regulate
expression of cellular genes [4]. In experimental biology,
RNAi has been widely used in identi¢cation and character-
ization of genes [14] and inhibition of viruses [15]. In func-
tional genomics, a large number of genes controlling cell di-
vision and metabolism have been identi¢ed by screening with
RNAi in the chromosome I and III of Caenorhabditis elegans
[16,17]. Another potential application is in the area of gene
therapy [18]. In mammalian cells, dsRNA larger than 30 bp
induces general non-speci¢c suppression of gene expression by
activating the antiviral interferon response [1]. This obstacle
was overcome by the discovery that the e¡ector in RNAi is
a siRNA which is 21^23 nt long with 2 nt 3P-overhang and
5P-phosphate. The successful gene silencing with chemically
synthesized 21^22 nt siRNA rapidly triggered its wide appli-
cation in mammalian cells [1^3].
Fig. 1. Schematic diagram of siRNA expressing adenovirus shuttle vector pShuttle-H1. This vector was derived from the promoterless adenovi-
rus shuttle vector pShuttle (Stratagene). The BglII site of the original promoterless pShuttle was converted to EcoRI by site-directed mutagene-
sis. Stem^loop producing oligonucleotides (for detail, refer to [5]) are cloned into the unique Bgl II and Hind III sites. Upon ligation, BglII site
is destroyed. The insert is con¢rmed with EcoRI digestion by distinguishing the 360 bp band of a positive clone from 300 bp band of an empty
vector. Polymerase III-dependent H1-RNA promoter drives the expression of 19 bp stem^9 nt loop RNA which is processed into functional
siRNA by cellular enzymes.
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It has been demonstrated that a vector derived from poly-
merase III-dependent H1-RNA gene promoter can produce
siRNA and cause e⁄cient and speci¢c downregulation of
gene expression, resulting in functional inactivation of the
targeted genes [5]. Almost all the elements of H1-RNA pro-
moter are located upstream the transcribed region; it is ideally
suited to the expression of V21 nt siRNA or V50 nt RNA
stem^loops. The stem^loop precursor transcript is generated
and processed to functional siRNA by cellular enzymes [5].
This small size of siRNA prevents activation of the dsRNA
inducible interferon system present in mammalian cells and
avoids the non-speci¢c phenotypes normally produced by
dsRNA larger than 30 bp in somatic cells.
The availability of high virus titer, infection of a broad
spectrum of cell types and independence on active cell division
makes adenovirus the vector of choice for siRNA delivery.
The human adenovirus serotype 5 was used in our system.
This is a replication defective adenovirus with deletion of
E1 and E3 genes which render this virus incapable of repli-
cation itself [13]. Moreover, this system makes use of the
e⁄cient homologous recombination in E. coli [13], to pro-
duce recombinant adenovirus by a double-recombination
event between cotransformed adenoviral backbone plasmid
pAdEasy-1 and a shuttle vector pShuttle-H1.
Here, we ¢rst constructed a new adenovirus shuttle vector
to express a stem^loop RNA with a 19 nt speci¢c stem and
9 nt loop which has been shown to e⁄ciently inactivate genes
[5]. The H1-RNA promoter was used in our strategy. H1-
RNA promoter was cloned into the promoterless shuttle vec-
tor pShuttle to get pShuttle-H1 which can drive the expression
of siRNA in recombinant adenovirus (Fig. 1). The 64 nt oli-
gonucleotide can be cloned into the pShuttle-H1 to express
siRNAs targeting di¡erent genes. In this pilot study, we tested
this system by targeting p53 gene as a model. Adenovirus
expressing siRNA targeting p53 was used to infect MCF-7
and A549 cells. In AdH1-p53 but not AdH1-empty infected
MCF-7 cells, p53 gene was e⁄ciently silenced both 48 and 72 h
post infection (Fig. 2B). Moreover, we also showed signi¢-
cant downregulation of p53 in A549 cells (Fig. 2C). It has
been well documented that pSUPER-p53 expresses siRNA
and e⁄ciently knocks down p53 in MCF-7 cells by electro-
poration [5]. Whereas, we failed to silence p53 in MCF-7 and
other cell lines by transfecting either pSUPER-53 or pShuttle-
H1-p53 with help of di¡erent commercial liposomes (data not
Fig. 2. Silencing p53 gene by adenovirus delivered siRNA. A: Schematic outline of a recombinant adenovirus expressing siRNA targeting
p53 (AdH1-p53). The 64 nt oligonucleotide encoding human p53 siRNA was inserted into the BglII and HindIII sites of pShuttle-H1 to get
pShuttle-H1-p53. The resultant plasmid was linearized with PmeI and cotransformed into E. coli BJ5183 cells with pAdEasy-1 adenoviral back-
bone plasmid. Recombinants (AdH1-p53) were selected for kanamycin resistance and con¢rmed by PacI analysis. AdH1-p53 was linearized
with PacI and transfected into AD-293 packaging cells to produce recombinant adenovirus. B: Silencing p53 gene in MCF-7 cells by adenovi-
rus delivered siRNA. In AdH1-p53 but not AdH1-empty infected MCF-7 cells, p53 gene was e⁄ciently silenced both 48 and 72 h after infec-
tion. Proteins were extracted from cells and p53 levels were checked by Western blot. The lower actin bands served as internal control for
equal total protein loading and speci¢city control. C: Silencing p53 gene in A549 cells by adenovirus delivered siRNA. In A549 cells, AdH1-
p53 but not mock or AdH1-empty signi¢cantly downregulated the expression of p53 gene.
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shown). This may be due to a low and uneven transfection of
plasmids in cultured cells. Consistent with the observation of
several groups [10^12], viral vectors can overcome these lim-
itations and infect cells uniformly and rapidly. Given the sim-
plicity of this system, which employs readily available re-
agents, most laboratories have the ability to silence their
genes by recombinant adenoviruses. The constructed pShut-
tle-H1 hosts unique BglI and HindIII sites for insertion of
oligonucleotides encoding siRNA (Fig. 1).
In conclusion, we developed a simple siRNA delivery strat-
egy by combination of well-de¢ned H1-RNA promoter and
conventional pAdEasy-1 adenovirus system. Our results dem-
onstrate signi¢cant downregulation of p53 expression in mam-
malian cells. With availability of high titers of adenoviruses
and uniform and rapid infection, this technology will have a
foreseeable wide application both in experimental biology and
molecular medicine.
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